KorinMi Raises INR 3 Cr to Expand Korean Skincare Clinics in India
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
KorinMi, a pioneering Korean skin clinic, has raised INR 3 crore (approx. USD 360,000) in a pre-seed funding round led by prominent angel investors including Vikas Agarwal, former CEO of Kaya Skin Clinic (UAE), and Vivek Kumar, CEO of Venture Garage, along with a network of CXOs and industry leaders.
The fresh capital will be strategically deployed to enhance technology, bolster marketing, expand clinic operations, and roll out a new line of skincare products customised for Indian skin using advanced Korean skincare science.
Founded in 2024 by Reshbha Munjal and Jenovia Daun Jung, KorinMi blends the clinical expertise of Korean dermatology with solutions tailored specifically for Indian skin. The brand's name—"Korin" (Korea + India) and "Mi" (meaning beauty in Korean)—embodies its mission to merge global beauty excellence with localised innovation.
KorinMi's cutting-edge clinics offer both non-invasive and invasive treatments backed by Korean dermatological science. A key differentiator is its 3D Korean skin analysis technology that evaluates over 15 skin parameters to deliver highly personalised care.
"While K-beauty enjoys immense popularity in India, professional clinics offering dermatologist-approved Korean treatments were missing," said Reshbha Munjal, Co-founder and CEO. "With KorinMi, we bridge this gap by offering authentic Korean solutions tailored to Indian skin needs."
Jenovia Daun Jung, Co-founder and COO, added, "We're offering a whole new category—professional K-beauty rooted in precision and results."
Investor Vikas Agarwal remarked, "What stood out was not just the strength of the concept, but the founders' vision and execution. KorinMi has already achieved profitability within six months—testament to the founders' operational excellence."
Having launched its flagship clinic in Gurugram just six months ago, KorinMi claims that it is already operationally profitable and has expanded to two locations in Delhi-NCR. The brand plans to scale rapidly with 25 clinics across major metros like Mumbai, Chennai, and Hyderabad over the next three years.
KorinMi is also entering the D2C space with a curated range of professional-grade Korean homecare products formulated for Indian skin. With five hero products launched, it aims to build a trusted skincare ecosystem across India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
8 minutes ago
- Entrepreneur
Avendus Future Leaders Fund III Invests INR 300 Cr in Aragen Life Sciences
The transaction involves the purchase of a minority stake and represents the fund's second investment from its third vintage, following its backing of La Renon Healthcare earlier this year. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Avendus Future Leaders Fund III, part of the Avendus Group, has led an INR 300 crore investment in Aragen Life Sciences, with participation from SBI Life Insurance. The transaction involves the purchase of a minority stake and represents the fund's second investment from its third vintage, following its backing of La Renon Healthcare earlier this year. The exact size of the stake acquired in Aragen has not been disclosed. Aragen Life Sciences, formerly known as GVK Biosciences, was founded in 2001 by G V Sanjay Reddy. Headquartered in Hyderabad, the company is a global research and development and manufacturing solutions provider to the life sciences industry. It offers services across the drug development cycle, from early-stage discovery to commercial manufacturing, for both small molecules and biologics. Under the leadership of chief executive Manni Kantipudi, Aragen has invested extensively in advanced technology platforms, as well as digital and artificial intelligence capabilities, to serve the needs of global drug innovators. Ritesh Chandra, Managing Partner of Avendus Future Leaders Fund, said, "Our investment in Aragen reflects our strong conviction in the CRDMO market in India. As global pharmaceutical companies increasingly turn to India for drug research, Aragen is well-positioned to capture these tailwinds." Kantipudi described Aragen as a trusted partner in the contract research, development, and manufacturing space. "We are excited to welcome Avendus and SBI Life Insurance as long-term shareholders," he said. The company's existing investors include Goldman Sachs and Quadria Capital. It stated that the fresh capital would help broaden its shareholder base and reinforce its role as a partner to pharmaceutical innovators around the world. Avendus Future Leaders Fund manages over INR 3,750 crore across its funds and focuses on investing in late-stage market leaders across sectors. Its portfolio includes Lenskart, Sagility, SBI General Insurance, Licious, Juspay, Zeta, Indegene, Veritas Finance, FirstCry, and Avanse Financial Services. The fund recently exited its investment in Juspay Technologies and earlier this year invested INR 160 crore in La Renon Healthcare. Chandra noted that the pharmaceutical sector is witnessing growth rates of 16 to 17 percent and forecast that India could approach China's 14 percent share of the global market within three to four years, up from the current 8 percent. He added that India's growing manufacturing capacity and abundant talent make it an attractive destination for global companies seeking to diversify supply chains. While the fund remains cautious on urban consumer markets, Chandra said rural consumption may offer greater resilience in the current economic environment.
Yahoo
19 minutes ago
- Yahoo
Asia FX firms as rate cut bets dent dollar; yen rises on BOJ rate hike speculation
Most Asian currencies firmed on Thursday, with the Japanese yen in the lead as the dollar was pressured by markets pricing in an interest rate cut by the Federal Reserve in September. The yen was boosted by increased speculation over a rate hike by the Bank of Japan, after U.S. Treasury Secretary Scott Bessent warned that the BOJ was falling behind in its efforts to curb inflation. Broader Asian markets benefited from improving risk appetite and a softer dollar, as markets priced in an almost 100% chance the Fed will cut rates in September. But bigger risk-on moves were held back by some caution over U.S. tariffs, especially as India raced to stave off steep duties on its exports to the country. Japanese yen gains on BOJ rate hike speculation The Japanese yen was the top performer in Asia, with the USDJPY pair sliding 0.5% to 146.72 yen. The yen was boosted by heightened speculation over the BOJ's plans to hike interest rates, especially after Bessent said the central bank will do so. Bessent told Bloomberg the BOJ was 'behind the curve' on inflation, and will need to raise rates. His comments contrast those from BOJ Governor Kazuo Ueda, who has largely dismissed concerns that the BOJ lagged in raising rates to quash sticky inflation. Ueda has also repeatedly signaled that the central bank will hike rates in tandem with higher inflation. But a series of soft inflation readings in recent months raised doubts over just when the BOJ could hike next. Analysts say the BOJ will be most likely to hike rates for a fourth time since early-2024 in September this year. Japanese second-quarter gross domestic product data is due on Friday, and is set to offer more cues on the country. While inflation has eased in recent months, core prices have still remained above the BOJ's 2% annual target. Dollar weak as markets confirm Sept rate cut The dollar index and dollar index futures both drifted lower on Thursday, extending overnight losses as markets priced in a greater chance the Fed will cut interest rates in September. Investors were seen pricing in a nearly 97% chance the Fed will cut rates by 25 basis points in September, amid increasing signs of cooling U.S. inflation and jobs growth, CME Fedwatch showed. The prospect of lower U.S. rates boosted most Asian currencies. The Chinese yuan's USDCNY fell slightly, extending declines from earlier this week after the U.S. and China agreed to extend their trade truce by 90 days. Focus is now on a string of key Chinese economic readings due on Friday, including industrial production and retail sales. The Australian dollar's AUDUSD pair rose marginally after data showed the country's labor market grew slightly below expectations in July. The print furthered the notion that Australia's labor sector was cooling, which stands to invite more interest rate cuts by the Reserve Bank. The Singapore dollar's USDSGD pair was flat, while the South Korean won's USDKRW rose 0.4%. The Indian rupee's USDINR pair steadied after falling sharply from record highs hit last week. But sentiment towards India remained clouded by the prospect of 50% U.S. tariffs against the country, over its purchase of Russian oil. U.S. President Donald Trump is set to meet Russian counterpart Vladimir Putin in Alaska on Friday to discuss the Ukraine war, with the meeting also expected to address Russia's oil industry. Related articles Asia FX firms as rate cut bets dent dollar; yen rises on BOJ rate hike speculation These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia After soaring 149%, this stock is back in our AI's favor - & already +25% in July Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
India's Age of Individualistic, Experimental Shoppers
Welcome to India Edition, I'm Menaka Doshi. Join me each week for a ringside view of the billionaires, businesses and policy decisions behind India's rise as an emerging economic powerhouse. You can subscribe here, and share feedback with me here.
